A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

New England Journal of Medicine

Volumn 356, Issue 6, 2007, Pages 580-592

  Krueger, Gerald G ^a,f   Langley, Richard G ^b   Leonardi, Craig ^c   Yeilding, Newman ^d   Guzzo, Cynthia ^d   Wang, Yuhua ^d   Dooley, Lisa T ^d   Lebwohl, Mark ^e  

^a UNIVERSITY OF UTAH   (United States)

^b DALHOUSIE UNIVERSITY   (Canada)

^c SAINT LOUIS UNIVERSITY   (United States)

^d CENTOCOR INC   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 12 23 ANTIBODY; INTERLEUKIN 23; MONOCLONAL ANTIBODY; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BASAL CELL CARCINOMA; CELLULITIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; INJECTION SITE REACTION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; PSORIASIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; STROKE; TREATMENT OUTCOME; URINARY TRACT INFECTION; VIRUS INFECTION;

EID: 33846889522     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa062382     Document Type: Article

References (34)

1. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996;14:485-96.
2. Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352:1899-912.
3. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7.
4. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534-42.
5. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74.
6. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22.
7. Schon MP, Detmar M, Parker CM. Murine psoriasis-like disorder induced by naive CD4+ T cells. Nat Med 1997;3:183-8.
8. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-46.
9. Yawalkar N, Karlen S, Hunger R, Brand CU, Braathen LR. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 1998;111:1053-7.
10. Hong K, Chu A, Ludviksson BR, Berg EL, Ehrhardt RO. IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J Immunol 1999;162:7480-91.
11. Tada Y, Asahina A, Takekoshi T, et al. Interleukin 12 production by monocytes from patients with psoriasis and its inhibition by ciclosporin A. Br J Dermatol 2006;154:1180-3.
12. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125-30.
13. Piskin G, Sylva-Steenland RMR, Bos JD, Teunissen MBM. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006;176:1908-15.
14. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715-25.
15. Aggarwal S, Ghilardi N, Xie M-H, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003;278:1910-4.
16. Kauffman CL, Aria N, Toichi E, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004;123:1037-44.
17. Gottlieb AB, Frederick BS, Everitt DE, McCormick TS. A phase 1 study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody administered subcutaneously in subjects with plaque psoriasis. J Am Acad Dermatol 2005;52:Suppl:172.
18. Barrie AM, Plevy SE. The interleukin-12 family of cytokines: therapeutic targets for inflammatory disease mediation. Clin Applied Immunol Rev 2005;5:225-40.
19. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15.
20. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
21. Conover WJ. Practical nonparametric statistics. 2nd ed. New York: John Wiley, 1980:318-27.
22. Shaffer JP. Modified sequentially rejective multiple test procedures. J Am Stat Assoc 1986;81:826-31.
23. 21 C.F.R. § 312.32 (revised as of April 1, 2006).
24. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004;50:859-66.
25. Kim Y-K, Suh I-B, Kim H, et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol Psychiatry 2002;7:1107-14.
26. Fieschi C, Casanova J-L. The role of interleukin-12 in human infectious diseases: only a faint signature. Eur J Immunol 2003;33:1461-4.
27. de Jong R, Altare F, Haagen IA, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 1998;280:1435-8.
28. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002;13:155-68.
29. Overwijk WW, de Visser KE, Tirion FH, et al. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol 2006;176:5213-22.
30. Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature 2006;442:461-5.
31. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719-27.
32. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004-13.
33. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002;46:1-23.
34. Bruch-Gerharz D, Fehsel K, Suschek C, Michel G, Ruzicka T, Kolb-Bachofen V. A proinflammatory activity of interleukin 8 in human skin: expression of the inducible nitric oxide synthase in psoriatic lesions and cultured keratinocytes. J Exp Med 1996;184:2007-12.